Table 5.
Effect of EADL pre-treatment on the levels of ALT, AST, ALP, and TB in PCM intoxicated rats.
| Group | Treatment | Dose (mg/kg) | ALT (U/L) | AST (U/L) | ALP (U/L) | TB (umol/L) |
|---|---|---|---|---|---|---|
| Normal control | Control | – | 15.8 ± 2.9 | 95.1 ± 5.9 | 115.7 ± 7.0 | 0.5 ± 0.2 |
| Negative control | DMSO + PCM* | – | 1714.3 ± 142.2a | 2266.2 ± 340.4a | 330.0 ± 42.4a | 4.1 ± 0.8a |
| Positive control | Silymarin + PCM* | 200 | 474.5 ± 82.2b | 690.9 ± 146.6b | 195.5 ± 11.1b | 2.3 ± 0.3b |
| Treatment | EADL + PCM* | 50 | 1024.4 ± 230.1b | 971.7 ± 226.1b | 377.8 ± 53.7 | 1.1 ± 0.2b |
| 250 | 608.9 ± 340.0b | 800.8 ± 291.0b | 225.0 ± 10.0b | 1.3 ± 0.4b | ||
| 500 | 108.7 ± 29.0b | 313.0 ± 66.0b | 198.5 ± 19.8b | 1.5 ± 0.3b |
Values are expressed as means ± S.E.M. of six replicates.
*PCM was administered in the dose of 3 mg/kg.
aSignificant different as compared to normal control, p < 0.05.
bSignificant different as compared to negative control, p < 0.05.